4mg twice daily: increase if necessary after 2-4 weeks to 10 -12mg daily in divided doses.
A meta-analysis of all randomised controlled trials done until 2009 has shown that the drug is an ineffective antidepressant relative to selective serotonin reuptake inhibitors . There is publication bias. It transpires that a number of the trials were completed after the drug was first licensed in parts of the EU in 1997 to comply with FDA requirements.
- ↑ Eyding D, Lelgemann M, Grouven U, Härter M, Kromp M, Kaiser T, Kerekes MF, Gerken M, Wieseler B. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ (Clinical research ed.). 2010; 341:c4737.(Epub)